Literature DB >> 17368685

Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice.

Daniela Fukue Fukushiro1, Juliana do Nascimento Alvarez, Julie Anne Obara Tatsu, Juliana Pedroso Moraes Vilela de Castro, Cibele Cristina Chinen, Roberto Frussa-Filho.   

Abstract

It has been empirically suggested that the high incidence of drug abuse in schizophrenic patients is related to chronic neuroleptic treatment. We investigated the effects of withdrawal from long-term administration of the typical neuroleptic haloperidol and/or the atypical agent ziprasidone on the acute locomotor stimulant effect of cocaine as well as on cocaine-induced conditioned place preference (CPP). In the first experiment, mice were i.p. treated with haloperidol (1.0 mg/kg) and/or ziprasidone (4.0 mg/kg) for 15 days. At 72 h after the last injection, animals received an i.p. injection of cocaine (10 mg/kg) and their locomotor activity was quantified. In the second experiment, mice were withdrawn from the same haloperidol or ziprasidone treatment schedule and submitted to CPP. Withdrawal from haloperidol (but not ziprasidone or ziprasidone plus haloperidol) increased both cocaine-induced hyperactivity and CPP. These findings indicate that withdrawal from long-term treatment with typical neuroleptic drugs such as haloperidol (but not the atypical compound ziprasidone) may enhance some behavioral effects of cocaine in mice which have been related to drug dependence in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368685     DOI: 10.1016/j.pnpbp.2007.01.025

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

Review 1.  Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

Authors:  Tong H Lee; Steven T Szabo; J Corey Fowler; Paolo Mannelli; O Barry Mangum; Wayne F Beyer; Ashwin Patkar; William C Wetsel
Journal:  Drug Alcohol Depend       Date:  2012-02-21       Impact factor: 4.492

2.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

3.  Obituary: Roberto Frussa-Filho (1960-2013).

Authors:  Laís F Berro
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

4.  Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.

Authors:  Alison A Williams; Wendy M Ingram; Sarah Levine; Jack Resnik; Christy M Kamel; James R Lish; Diana I Elizalde; Scott A Janowski; Joseph Shoker; Alexey Kozlenkov; Javier González-Maeso; Amelia L Gallitano
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

5.  Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

6.  A Nonrewarding NMDA Receptor Antagonist Impairs the Acquisition, Consolidation, and Expression of Morphine Conditioned Place Preference in Mice.

Authors:  Lediane Tomazi; Carlos Fernando Mello; Ana Paula Schöffer; Bruna Amanda Girardi; Pâmella Karina Santana Frühauf; Maribel Antonello Rubin
Journal:  Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.590

7.  Spermidine, a positive modulator of the NMDA receptor, facilitates extinction and prevents the reinstatement of morphine-induced conditioned place preference in mice.

Authors:  Bruna A Girardi; Shaiana Fabbrin; Arithane L Wendel; Carlos F Mello; Maribel A Rubin
Journal:  Psychopharmacology (Berl)       Date:  2019-12-11       Impact factor: 4.530

Review 8.  Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Authors:  Henk S Temmingh; Taryn Williams; Nandi Siegfried; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

Review 9.  Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders.

Authors:  Ken W Grasing; Kim Burnell; Alok De
Journal:  Behav Pharmacol       Date:  2022-03-23       Impact factor: 2.277

10.  Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

Authors:  Chia-Hao Ma; Hung-Yu Chan; Ming H Hsieh; Chen-Chung Liu; Chih-Min Liu; Hai-Gwo Hwu; Ching-Hua Kuo; Wei J Chen; Tzung-Jeng Hwang
Journal:  Ther Adv Psychopharmacol       Date:  2022-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.